Matteo G. Della Porta,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Emilio Paolo Alessandrino,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Andrea Bacigalupo,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Maria Teresa van Lint,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Luca Malcovati,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Cristiana Pascutto,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Michele Falda,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Massimo Bernardi,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Francesco Onida,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Stefano Guidi,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Anna Paola Iori,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Raffaella Cerretti,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Paola Marenco,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Pietro Pioltelli,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Emanuele Angelucci,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Rosi Oneto,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Francesco Ripamonti,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Paolo Bernasconi,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Alberto Bosi,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Mario Cazzola,on behalf of Gruppo Italiano Trapianto di Midollo Osseo,Alessandro Rambaldi,on behalf of Gruppo Italiano Trapianto di Midollo Osseo

View Articletitled, Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

Supplemental data

GENE THERAPY

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
Clinical Trials & Observations

Saar Gill,Sarah K. Tasian,Marco Ruella,Olga Shestova,Yong Li,David L. Porter,Martin Carroll,Gwenn Danet-Desnoyers,John Scholler,Stephan A. Grupp,Carl H. June,Michael Kalos

View Articletitled, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Supplemental data

LYMPHOID NEOPLASIA

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy

Patricia S. Hähnel,Birgit Enders,Daniel Sasca,Wynand P. Roos,Bernd Kaina,Lars Bullinger,Matthias Theobald,Thomas Kindler

View Articletitled, Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy

Supplemental data

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Alexander J. A. Deutsch,Beate Rinner,Kerstin Wenzl,Martin Pichler,Katharina Troppan,Elisabeth Steinbauer,Daniela Schwarzenbacher,Sonja Reitter,Julia Feichtinger,Sascha Tierling,Andreas Prokesch,Marcel Scheideler,Anne Krogsdam,Gerhard G. Thallinger,Helmut Schaider,Christine Beham-Schmid,Peter Neumeister

View Articletitled, NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Supplemental data

Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness

Monica Messina,Ilaria Del Giudice,Hossein Khiabanian,Davide Rossi,Sabina Chiaretti,Silvia Rasi,Valeria Spina,Antony B. Holmes,Marilisa Marinelli,Giulia Fabbri,Alfonso Piciocchi,Francesca R. Mauro,Anna Guarini,Gianluca Gaidano,Riccardo Dalla-Favera,Laura Pasqualucci,Raul Rabadan,Robin Foà

View Articletitled, Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness

Supplemental data

MYELOID NEOPLASIA

Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation

Loveena Rishi,Maura Hannon,Mara Salomè,Marie Hasemann,Anne-Katrine Frank,Joana Campos,Jennifer Timoney,Caitriona O’Connor,Mary R. Cahill,Bo Porse,Karen Keeshan

View Articletitled, Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation

Supplemental data

IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1

Mo-Ying Hsieh,Richard A. Van Etten

View Articletitled, IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1

Supplemental data

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML
Brief Report

Violaine Havelange,Parvathi Ranganathan,Susan Geyer,Deedra Nicolet,Xiaomeng Huang,Xueyan Yu,Stefano Volinia,Steven M. Kornblau,Michael Andreeff,Carlo M. Croce,Guido Marcucci,Clara D. Bloomfield,Ramiro Garzon

View Articletitled, Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML

Supplemental data

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
Brief Report

Elisa Rumi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Ashot S. Harutyunyan,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Daniela Pietra,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Jelena D. Milosevic,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Ilaria C. Casetti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Marta Bellini,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Nicole C. C. Them,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Chiara Cavalloni,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Virginia V. Ferretti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Chiara Milanesi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Tiina Berg,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Emanuela Sant’Antonio,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Emanuela Boveri,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Cristiana Pascutto,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Cesare Astori,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Robert Kralovics,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Mario Cazzola,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

View Articletitled, CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Supplemental data

THROMBOSIS AND HEMOSTASIS

Novel FV mutation (W1920R, FV_Nara) associated with serious deep vein thrombosis and more potent APC resistance relative to FV_Leiden

Keiji Nogami,Keiko Shinozawa,Kenichi Ogiwara,Tomoko Matsumoto,Kagehiro Amano,Katsuyuki Fukutake,Midori Shima

View Articletitled, Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden

VASCULAR BIOLOGY

Sonic hedgehog mediates a novel pathway of PDGF-BB–dependent vessel maturation

Qinyu Yao,Marie-Ange Renault,Candice Chapouly,Soizic Vandierdonck,Isabelle Belloc,Béatrice Jaspard-Vinassa,Jean-Marie Daniel-Lamazière,Muriel Laffargue,Aksam Merched,Claude Desgranges,Alain-Pierre Gadeau

View Articletitled, Sonic hedgehog mediates a novel pathway of PDGF-BB–dependent vessel maturation

Supplemental data

Cover Image

Cover Image

This is a confocal microscope image of activated NF-κB (nuclear RelA) in BCR-ABL1–transformed mouse pre-B lymphoblasts. RelA staining is detected by anti-p65/RelA antibody and Alexa Fluor 555–conjugated goat anti-rabbit antibody (red color), with nuclei counterstained with DAPI (blue color). Imaged with a Leica TCS SP2 confocal microscope. See the article by Hsieh and Van Etten on page 2401.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Licking the wound with procoagulant vesicles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

CAR T-cells in autoimmunity: game changer or stepping stone?

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Table of Contents

EDITORIAL

Introduction to the series of reviews on “Antibody Derivatives as New Therapeutics for Hematologic Malignancies”
Clinical Trials & Observations

INSIDE BLOOD COMMENTARIES

Sonic hedgehog causes mural cells to jump ‘n’ run

A WHIM satisfactorily addressed
Clinical Trials & Observations

FV and APC resistance: the plot thickens

BLOOD WORK

Cytomegalovirus-associated hemophagocytic lymphohistiocytosis in a patient with myasthenia gravis treated with azathioprine

Cloaked in a starry sky

REVIEW SERIES

Advances in the treatment of hematologic malignancies using immunoconjugates
Clinical Trials & Observations

HOW I TREAT

How we treat sickle hepatopathy and liver transplantation in adults

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor
Clinical Trials & Observations

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Clinical Trials & Observations

Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL–positive acute lymphoblastic leukemia
Clinical Trials & Observations

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
Clinical Trials & Observations

GENE THERAPY

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
Clinical Trials & Observations

LYMPHOID NEOPLASIA

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness

MYELOID NEOPLASIA

Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation

IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML
Brief Report

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
Brief Report

THROMBOSIS AND HEMOSTASIS

Novel FV mutation (W1920R, FV_Nara) associated with serious deep vein thrombosis and more potent APC resistance relative to FV_Leiden

VASCULAR BIOLOGY

Sonic hedgehog mediates a novel pathway of PDGF-BB–dependent vessel maturation

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

EDITORIAL

Introduction to the series of reviews on “Antibody Derivatives as New Therapeutics for Hematologic Malignancies” Clinical Trials & Observations

INSIDE BLOOD COMMENTARIES

A WHIM satisfactorily addressed Clinical Trials & Observations

BLOOD WORK

REVIEW SERIES

Advances in the treatment of hematologic malignancies using immunoconjugates Clinical Trials & Observations

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor Clinical Trials & Observations

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study Clinical Trials & Observations

Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL–positive acute lymphoblastic leukemia Clinical Trials & Observations

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R Clinical Trials & Observations

GENE THERAPY

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells Clinical Trials & Observations

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML Brief Report

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis Brief Report

THROMBOSIS AND HEMOSTASIS

VASCULAR BIOLOGY

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Introduction to the series of reviews on “Antibody Derivatives as New Therapeutics for Hematologic Malignancies”
Clinical Trials & Observations

A WHIM satisfactorily addressed
Clinical Trials & Observations

Advances in the treatment of hematologic malignancies using immunoconjugates
Clinical Trials & Observations

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor
Clinical Trials & Observations

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Clinical Trials & Observations

Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL–positive acute lymphoblastic leukemia
Clinical Trials & Observations

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
Clinical Trials & Observations

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
Clinical Trials & Observations

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML
Brief Report

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
Brief Report